



## Original article

## Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital

Noemi Busquets<sup>a</sup>, Carmen Gómez Vaquero<sup>b</sup>, Jesús Rodríguez Moreno<sup>b</sup>, Daniel Roig Vilaseca<sup>c</sup>, Javier Narvâez<sup>b</sup>, Loreto Carmona<sup>d,e</sup>, Joan M. Nolla<sup>b,\*</sup>

<sup>a</sup> Servicio de Reumatología, Hospital General de Granollers, Granollers, Barcelona, Spain

<sup>b</sup> Servicio de Reumatología, IDIBELL-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

<sup>c</sup> Servicio de Reumatología, Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain

<sup>d</sup> Facultad de Ciencias de la Salud, Universidad Camilo José Cela, Madrid, Spain

<sup>e</sup> Instituto de Salud Musculoesquelética, Madrid, Spain

## ARTICLE INFO

## Article history:

Received 27 March 2013

Accepted 8 July 2013

Available online 19 September 2013

## Keywords:

Psoriatic arthritis  
Bone mineral density  
Bone densitometry  
Osteoporosis  
Fractures

## ABSTRACT

**Objective:** To assess the bone mineral density (BMD) and the frequency of osteoporosis and clinical fractures in a large group of Spanish patients with psoriatic arthritis (PsA).

**Patients and methods:** BMD was determined by DXA in all the patients who were willing to participate and had peripheral PsA regularly evaluated in a tertiary university hospital. All patients underwent a physical examination and general laboratory analysis. We gathered demographic and clinical variables related with BMD and risk of fractures. We also recorded the history of clinical low impact fractures. The population of reference to calculate T-score and Z-score came from a Spanish database.

**Results:** One hundred and fifty-five patients were included (64 postmenopausal women, 26 premenopausal women and 65 men). The clinical forms of PsA were: 46% oligoarticular and 54% polyarticular. Mean disease duration was 13.7 ± 9.4 years and mean ESR was 21.8 ± 13.9 mm/h; 66% of patients had received glucocorticoid treatment.

We found no differences in BMD status between the patients and the Spanish general population, neither in the whole series nor in each defined subgroup. Frequency of osteoporosis was 16%; it was higher in postmenopausal women (28%) than in men (9%) or premenopausal women (4%). Frequency of clinical fractures was 13%; it accounted specially in postmenopausal women.

**Conclusions:** The magnitude of the problem of osteoporosis in PsA seems to be mild.

© 2013 Elsevier España, S.L. All rights reserved.

### Estado de la densidad mineral ósea y frecuencia de osteoporosis y de fracturas clínicas en 155 pacientes con artritis psoriásica evaluados en un hospital universitario

## RESUMEN

**Objetivo:** Analizar el estado de la densidad mineral ósea (DMO) así como la frecuencia de osteoporosis y de fracturas clínicas en una serie de pacientes con artritis psoriásica (APs).

**Pacientes y Método:** Se determinó la DMO, mediante DXA, en todos los pacientes con APs periférica, evaluados de forma periódica en un hospital universitario, que aceptaron participar en el estudio. Se les practicó una exploración física y un estudio analítico y se recabó información acerca de variables clínicas relacionadas con la DMO y con el riesgo de fractura. Asimismo, se analizó si existía el antecedente de haber presentado una fractura de bajo impacto. El cálculo del T-score y del Z-score se realizó a partir de una base de datos de población española.

**Resultados:** Se incluyeron 155 pacientes (64 mujeres posmenopáusicas, 26 mujeres premenopáusicas y 65 varones). En el 46% de los casos la APS adoptó un patrón oligoarticular y en el 54% poliarticular. La duración media de la enfermedad fue 13.7 ± 9.4 años, el valor medio de la VSG fue de 21.8 ± 13.9 mm/h; el 66% de los pacientes habían recibido tratamiento con glucocorticoides.

## Palabras clave:

Artritis psoriásica  
Densidad mineral ósea  
Densitometría ósea  
Osteoporosis  
Fracturas

\* Corresponding author.

E-mail address: [jm.nolla@bellvitgehospital.cat](mailto:jm.nolla@bellvitgehospital.cat) (J.M. Nolla).

No se observaron diferencias entre la DMO de los pacientes y la de la población general, ni en la globalidad de la serie, ni en ninguno de los tres grupos. La frecuencia global de osteoporosis se situó en el 16%; fue más alta en las mujeres posmenopáusicas (28%) que en los varones (9%) y que en las mujeres premenopáusicas (4%). La frecuencia de fracturas clínicas fue del 13%; acontecieron fundamentalmente en las mujeres posmenopáusicas.

© 2013 Elsevier España, S.L. Todos los derechos reservados.

Chronic inflammation, including autoimmune disease, is a strong trigger for the development of osteoporosis<sup>1</sup>.

Rheumatoid arthritis (RA) is the paradigm of chronic inflammatory diseases that are frequently accompanied by bone loss. It has been long recognized that osteoporosis is a relevant co-morbid condition in both female<sup>2</sup> and male<sup>3</sup> patients with RA. Disease activity, decreased functional capacity, and corticosteroid use have been identified as the most important causative factors.<sup>4</sup>

Psoriasis<sup>5</sup> and psoriatic arthritis (PsA)<sup>6,7</sup> are chronic, immunomediated inflammatory diseases characterized by abnormal expressions of keratinocytes, as well as proliferation and neovascularization of the synovial.

Although patients with PsA seem to have local and systemic osteoporosis,<sup>8</sup> little is known concerning the actual degree of bone loss. Nowadays, certain issues, specially related to the magnitude of the problem in practice, remain to be clarified.<sup>9</sup>

We report a cross-sectional study that used dual X-ray absorptiometry (DXA) to evaluate BMD at the lumbar spine and the hip and the frequency of osteoporosis and clinical fractures in 155 Spanish patients with peripheral PsA.

## Patients and methods

### Study setting

The study was performed at the Rheumatology Department of the Hospital Universitari de Bellvitge. Our department has developed a standardized protocol to collect information on PsA patients. Collected data include medical history, physical, laboratory and imaging study findings, and management.

### Patients

We considered for the current study all PsA patients who had been attended within one-year period ( $n=202$ ) in our outpatient clinics.

We excluded patients who met any of the following criteria: (a) disease duration <1 year ( $n=12$ ), (b) evidence of ankylosing spondylitis (psoriatic spondyloarthropathy) ( $n=18$ ) and (c) current clinical remission, defined as the absence of articular signs and symptoms for the last 6 months ( $n=14$ ). Patients with axial involvement were excluded in order to avoid interferences in BMD measurement due to syndesmophytes.

One hundred and fifty-eight patients were invited to participate in the study; 155 gave their informed consent. All patients fulfilled the diagnostic criteria for PsA defined by the Classification of Psoriatic Arthritis (CASPAR) study.<sup>10</sup> None had received hormone replacement therapy or any drug for osteoporosis treatment other than calcium or vitamin D.

### Outcome measure

A full medical history was obtained and a complete physical examination was undergone. The following data were recorded: (1) gender, (2) menopausal status, (3) age, (4) body mass index (BMI), (5) duration of PsA, (6) type of PsA: oligoarticular (one to four swollen joints) or polyarticular (five or more swollen joints),

(7) cutaneous involvement, (8) onychopathy, (9) uveitis, (10) glucocorticoid treatment, (11) disease modifying anti-rheumatic drugs (DMARD) use, (12) biological therapy use, (13) erythrocyte sedimentation rate evaluated by the Westergren method (the value of the last routine determination was considered), (14) functional status; it was measured by the modified Health Assessment Questionnaire (mHAQ), and (15) personal history of low impact fractures. All patients were referred to the Bone Densitometry Unit of our department. BMD ( $\text{g}/\text{cm}^2$ ) was measured at the lumbar spine (L2–L4) and the hip by DXA (Hologic QDR 4500, Hologic Inc., Waltham, MA). The T-score (comparison with normal subjects of the same sex with peak bone mass) and the Z-score (comparison with age and sex matched normal controls) were established by comparison with data from the study of BMD at the lumbar spine and femoral neck in a Spanish population performed by the Multicentre Research Project on Osteoporosis (MRPO).<sup>11</sup>

Osteopenia (T-score between  $-1.0$  and  $-2.5$ ) and osteoporosis (T-score below  $-2.5$ ) were defined according to the criteria of the World Health Organization.<sup>12</sup> Additionally, according to the International Society of Clinical Densitometry,<sup>13</sup> in premenopausal women and in male younger than 50 years, we calculated the percentage of patients that presented a BMD below the expected range for age (Z-score of  $-2$  or lower).

In 2 patients with bilateral hip prosthesis, only lumbar BMD was available. In other 2 patients, lumbar BMD was not determined because of the antecedent of instrumented surgery of the spine.

### Statistical analysis

The study variables were tabulated as means and standard deviations (SD), or proportions as applicable. Confidence interval (CI) was used to assess the difference between the mean Z-score at each site and the general population. Differences between groups of patients were assessed by ANOVA and chi squared tests. Statistical significance was set at  $p < 0.05$ .

## Results

Table 1 shows the demographic and clinical characteristics of the patients included in the study.

Table 2 shows the densitometric status of the patients included in the study.

Table 3 shows the frequency of osteoporosis according to the WHO criteria in the whole series and in each defined subgroup.

In premenopausal women, the frequency of patients, that presented, in at least one of the evaluated sites, a BMD below the expected range for age was 15% (4/26); in males younger than 50, it was 19% (4/21).

Fifty-nine (38%) patients had a normal BMD (T-score  $\geq -1$  SD) both in the lumbar spine and hip (femoral neck and total hip). Patients with a normal BMD were younger ( $52.05 \pm 11.92$  vs  $57.59 \pm 14.07$  years,  $p < 0.05$ ), had a shorter duration of PsA ( $11.00 \pm 7.39$  vs  $15.33 \pm 10.11$  years,  $p < 0.01$ ), had a higher BMI ( $28.69 \pm 5.19$  vs  $26.28 \pm 4.43$ ,  $p < 0.01$ ) and presented a better HAQ ( $0.51 \pm 0.46$  vs  $0.78 \pm 0.67$ ,  $p < 0.01$ ).

No differences were found in BMD between patients with oligoarticular and polyarticular involvement.

**Table 1**  
Demographic and clinical characteristics of patients.

	Overall series (n = 155)	Premenopausal women (n = 26)	Postmenopausal women (n = 64)	Male (n = 65)
Age, years	55.51 ± 13.53	39.35 ± 6.74	62.63 ± 8.03	55.06 ± 14.18
Body mass index, kg/m <sup>2</sup>	27.20 ± 4.86	25.67 ± 6.12	28.25 ± 5.02	26.88 ± 3.92
PsA duration, years	13.65 ± 9.37	9.12 ± 6.95	15.60 ± 8.57	13.57 ± 10.41
Type of PsA				
• Oligoarticular	71 (46%)	15 (58%)	32 (50%)	24 (37%)
• Polyarticular	84 (54%)	11 (42%)	32 (50%)	41 (63%)
Cutaneous involvement	148 (96%)	25 (96%)	62 (97%)	61 (94%)
Onychophathy	91 (59%)	13 (50%)	35 (55%)	43 (66%)
Uveitis	3 (2%)	–	2 (3%)	1 (2%)
Glucocorticoids				
• Ever users	102 (66%)	13 (50%)	45 (70%)	44 (68%)
• Cumulative dose, g	3.21 ± 5.89	1.31 ± 3.50	3.56 ± 6.03	3.64 ± 6.45
DMARD				
Ever users	131 (85%)	21 (81%)	63 (83%)	57 (88%)
Biological therapy				
Ever users	23 (15%)	6 (23%)	9 (14%)	8 (12%)
ESR, mm/h	21.84 ± 13.85	21.40 ± 12.72	25.37 ± 15.04	18.31 ± 12.26
HAQ	0.68 ± 0.61	0.50 ± 0.46	0.99 ± 0.68	0.44 ± 0.44

PsA: psoriatic arthritis; DMARD: disease modifying anti-rheumatic drugs; ESR: erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire.

**Table 2**  
Densitometric status of the patients.

	Lumbar spine	Femoral neck	Total hip
Overall series (n = 155)			
BMD, g/cm <sup>2</sup>	0.964 ± 0.135	0.766 ± 0.128	0.901 ± 0.151
T-score (95% CI)	−0.63 ± 1.24 (−3.6 to 2.8)	−0.80 ± 1.13 (−3.5 to 3.1)	−0.92 ± 1.16 (−3.2 to 2.9)
Z-score (95% CI)	0.1 ± 0.97 (−2.1 to 3.0)	−0.01 ± 1.11 (−2.2 to 3.9)	−0.07 ± 1.17 (−2.7 to 3.6)
Female (n = 90)			
BMD, g/cm <sup>2</sup>	0.945 ± 0.141	0.743 ± 0.128	0.860 ± 0.147
T-score (95% CI)	−0.87 ± 1.36 (−1.2 to −0.6)	−0.79 ± 1.25 (−1.1 to −0.5)	−0.97 ± 1.24 (−1.2 to −0.7)
Z-score (95% CI)	0.20 ± 1.04 (−0.1 to 0.4)	−0.10 ± 1.15 (−0.2 to 0.3)	−0.56 ± 1.20 (−0.3 to 0.2)
Premenopausal women (n = 26)			
BMD, g/cm <sup>2</sup>	1.033 ± 0.108	0.807 ± 0.103	0.906 ± 0.134
T-score (95% CI)	−0.02 ± 1.03 (−0.44 to 0.40)	−0.17 ± 1.03 (−0.5 to 0.24)	−0.60 ± 1.15 (−1.06 to −0.13)
Z-score (95% CI)	0.07 ± 1.01 (−0.33 to 0.48)	−0.10 ± 1.01 (−0.51 to 0.31)	−0.40 ± 1.19 (−0.88 to 0.08)
Postmenopausal women (n = 64)			
BMD, g/cm <sup>2</sup>	0.909 ± 0.138	0.717 ± 0.128	0.840 ± 0.149
T-score (95% CI)	−1.22 ± 1.33 (−1.56 to −0.89)	−1.04 ± 1.24 (−1.36 to 0.73)	−1.12 ± 1.25 (−1.44 to −0.81)
Z-score (95% CI)	0.26 ± 1.06 (−0.01 to 0.53)	0.18 ± 1.20 (−0.13 to 0.48)	0.08 ± 1.19 (−0.22 to 0.38)
Male (n = 65)			
BMD, g/cm <sup>2</sup>	0.991 ± 0.121	0.797 ± 0.122	0.957 ± 0.138
T-score (95% CI)	−0.31 ± 0.96 (−0.6 to −0.1)	−0.83 ± 0.96 (−1.1 to −0.6)	−0.86 ± 1.06 (−1.1 to −0.6)
Z-score (95% CI)	−0.03 ± 0.86 (−0.2 to 0.2)	−0.17 ± 1.05 (−0.4 to 0.1)	−0.09 ± 1.12 (−0.4 to 0.2)

BMD: bone mineral density.

**Table 3**  
Frequency of osteoporosis in the overall series and in each defined subgroup.

	Lumbar spine	Femoral neck	Total hip	Any site
Overall series (n = 155) (95%CI)	7% (4%–12%)	6% (3%–11%)	11% (7%–17%)	16% (11%–23%)
Premenopausal women (n = 26) (95%CI)	–	–	4% (1%–19%)	4% (1%–19%)
Postmenopausal women (n = 64) (95%CI)	17% (10%–28%)	13% (7%–23%)	16% (9%–26%)	28% (19%–40%)
Men (n = 65) (95%CI)	–	1% (0%–8%)	9% (4%–19%)	9% (4%–19%)

**Table 4**  
Comparison between the reported data of Frediani et al. (17), Hofbauer et al. (18) and the present study.

	Frediani et al. (17)	Hofbauer et al. (18)	Present study
Number	186	116	155
Age, years	63 ± 6	52 ± 13	56 ± 14
Female/male	125/61	57/59	90/65
Postmenopausal women	65 (35%)	35 (61%)	64 (41%)
Body mass index, kg/m <sup>2</sup>	22.3 ± 2.8	–	27.20 ± 4.86
ESR, mm/h	21 ± 7	16 ± 11	21.8 ± 13.9
HAQ	0.6 ± 0.1	0.78 ± 1.08	0.68 ± 0.61
Lumbar T-score	–	–0.02 ± 1.50	–0.63 ± 1.24
Lumbar Z-score	–	0.18 ± 1.52	0.1 ± 0.97
Femoral T-score	–	–0.39 ± 1.17	–0.80 ± 1.13
Femoral Z-score	–	0.08 ± 1.07	–0.01 ± 1.11
<b>Osteopenia</b>			
• Premenopausal women	56%		35%
• Postmenopausal women	53%	35%	61%
• Men	51%	31%	51%
<b>Osteoporosis</b>			
• Premenopausal women	11%		4%
• Postmenopausal women	47%	2%	28%
• Men	29%	10%	9%

ESR: erythrocyte sedimentation rate. HAQ: Health Assessment Questionnaire.

Thirteen percent of the patients (19/155) had had a clinical low-trauma fracture. This complication accounted specially in postmenopausal women (16 cases, 84%). The most frequent localization was the forearm (10 cases); one case of vertebral fracture and another of hip fracture were found. Clinical and demographic data were similar in patients with and without fracture.

## Discussion

We have analyzed the BMD status, the frequency of osteoporosis and the clinical fractures in a large group of Spanish patients with PsA. We found no differences in BMD status between the patients and the Spanish general population. In the overall series, frequency of osteoporosis was 16% and frequency of clinical fractures, 13%. As expected, frequency of osteoporosis was clearly higher in postmenopausal women (28%) than in men (9%) or premenopausal women (4%); in this way, the majority of clinical fractures accounted in postmenopausal women.

To date, few studies are available in which BMD has been evaluated, using DXA, in patients with psoriasis and, more surprisingly, in patients with PsA.

In a recent study, Dreier et al.<sup>14</sup> analyzed the prevalence of osteoporosis in a large database of patients with psoriasis (7936 subjects). No difference was found among women, while among men, patients with psoriasis showed a higher prevalence than controls (14.835 subjects).

Unfortunately, the studies that identify patients with arthritis deal with smaller sample sizes. In the 1990s, our group<sup>15</sup> measured BMD in 52 patients with PsA (14 premenopausal women, 19 postmenopausal women and 19 men); the only difference in densitometric data was at the femoral neck in the postmenopausal subgroup, with a BMD significantly lower than in controls. More recently, Borman et al.<sup>16</sup> evaluated, by DXA, BMD at lumbar spine and total hip in a series of 47 patients (24 premenopausal women, 23 men) with psoriasis (18 with PsA). There was no significant difference between the BMD levels of psoriatic patients with and without arthropathy.

Only two studies<sup>17,18</sup> on the prevalence of osteoporosis in patients with PsA include a substantial number of subjects.

Frediani et al.<sup>17</sup> studied 186 patients with peripheral PsA and 100 healthy subjects, equally distributed in 3 groups: women of child-bearing age, women in menopause and men. No patient

had received previously steroid treatment. BMD was significantly lower in the arthritic than in the healthy subjects regardless of gender, menopausal status, or age, as expressed in g/cm<sup>2</sup> or by T and Z scores. Among PsA patients, osteoporosis in at least one skeletal region was observed in 11% of premenopausal women, 47% of postmenopausal women and 29% of men. In the whole series, age, BMI and HAQ were significant predictors of bone mass.

Hofbauer et al.<sup>18</sup> studied 116 patients with peripheral PsA, 57 women (mean age 56 ± 11 yrs, 61% postmenopausal) and 59 men (mean age 49 ± 13 yrs). None of the patients had received glucocorticoids or DMARDs for the last 12 months and no patient had a history of long-term (>6 months) glucocorticoid therapy. Osteoporosis was detected in only one woman (1.75%), but in six men (10.2%).

As Table 4 shows, the frequency of osteoporosis found in the present study is situated in an intermediate position with respect to the obtained by Frediani et al.<sup>17</sup> and Hofbauer et al.<sup>18</sup>. The discrepancies between the results of these three studies probably may be ascribable to differences in the demographical, clinical and therapeutic variables with capacity to influence over bone mass.

In any case, it seems that it is possible to support that the intensity of bone loss in PsA is lower than the observed in RA, the major inflammatory arthropathy. PsA differs from RA in several ways, including more intermittent disease activity, milder inflammation, milder functional impairment, and less frequent use of glucocorticoids; these differences may result in a better bone mass preservation in PsA as compared to RA. Additionally, the difference in bone involvement between the two diseases could be largely determined by a different balance and expression of the factors controlling the coupling cycle of bone remodelling<sup>8</sup>.

There is a relevant absence of data on fracture in patients with PsA. Information is available only in one recent study, published by Pedreira et al.<sup>19</sup> Data refer to a sample of 45 postmenopausal women with PsA (mean age: 60.5 ± 8.7 yrs), 52 patients with psoriasis (mean age: 61.4 ± 9.1 yrs) and 98 healthy controls. The prevalence of fragility fractures among patients with PsA (33%) was significantly greater than that observed in patients with psoriasis (28.8%). Both prevalence rates are reported as significantly greater compared to controls, but prevalence of fractures in controls is not provided. Interestingly, BMD data of lumbar spine and proximal femur are not significantly different in the 3 groups.

The frequency of fractures observed in the present study (13%) was clearly minor. Probably, this fact is consequence that, unlike Pedreira et al., we have not performed a thoracic and lumbar spine-X-ray analysis, in search of radiological vertebral fractures, a circumstance that constitutes a clear limitation of our study. However, every day clinical practice seems to suggest that osteoporotic fracture is not a prominent feature of the course PsA and the obtained data support this assumption. In fact, when we previously analyzed 669 patients with osteoporotic vertebral fracture diagnosed in our department over a 10-year period, only one case of PsA was observed.<sup>20</sup>

Our data, and the literature review, suggest that the magnitude of the problem of osteoporosis in PsA is mild. Nevertheless, it seems necessary to design large longitudinal prospective studies in order to characterize definitively the bone loss accounting in PsA patients. In addition, we need fracture studies than can define the risk of such an important complication, which may depend largely on factors other than BMD alone.

### Opinion

Osteoporosis does not appear to be a significant problem in patients with psoriatic arthritis.

### Ethical responsibilities

**Protection of people and animals.** The authors declare that this research experiments have not been done in humans or animals.

**Confidentiality of data.** Confidentiality of data. The authors declare that they have followed the protocols of their workplace on the publication of data from patients and that all patients included in the study have received sufficient information and have given their informed consent to participate in the study.

### Conflict of interest

The authors declare that they have no conflict of interests.

### References

1. Braun T, Schett G. Pathways for bone loss in inflammatory disease. *Curr Osteoporosis Rep.* 2012;10:101–8.
2. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. *Arthritis Rheum.* 2000;43:522–30.
3. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. *Arthritis Rheum.* 2006;54:3104–12.
4. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Reduced bone mineral density in male rheumatoid arthritis patients: frequency and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. *Arthritis Rheum.* 2000;43:2776–84.
5. Nestle FO, Kaplan DH, Barker J. Psoriasis. *N Engl J Med.* 2009;361:496–509.
6. Gonzalez S, Queiro R, Ballina J. Actualización en la patogenia de la artritis psoriásica. *Reumatol Clin.* 2012;8(S1):S1–6.
7. Cañete JD. Biopatología de la membrana sinovial en la artritis psoriásica. *Reumatol Clin.* 2012;8(S1):S10–4.
8. Del Puente A, Esposito A, Parisi A, Atteno M, Montalbano S, Vitiello M, et al. Osteoporosis and psoriatic arthritis. *J Rheumatol.* 2012;89:36–8.
9. Husni ME, Mease PJ. Managing comorbid disease in patients with psoriatic arthritis. *Curr Rheumatol Rep.* 2010;12:281–7.
10. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum.* 2006;54:2665–73.
11. Diaz Curiel M, Carrasco de la Peña JL, Honorato Perez J, Pérez Cano R, Rapado A, Ruiz Martínez I, on behalf of the Multicentre Research Project on Osteoporosis. Study of bone mineral density in lumbar spine and femoral neck in a Spanish population. *Osteoporosis Int.* 1997;7:59–64.
12. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 843. Geneva: WHO; 1994.
13. Leib ES, Binkley N, Bilezikian JP, Kendler DL, Lewiecki M, Petak SM. Position development conference of the International Society for Clinical, Densitometry, Vancouver, BC, July 15–17, 2005. *J Rheumatol.* 2006;33:2319–21.
14. Dreijer J, Weitzman D, Cohen AD. Psoriasis and osteoporosis: a sex-specific association. *J Invest Dermatol.* 2009;129:1643–9.
15. Nolla JM, Fiter J, Rozadilla A, Gomez-Vaquero C, Mateo L, Rodriguez-Moreno J, et al. Bone mineral density in patients with peripheral psoriatic arthritis. *Rev Rhum [Engl Ed].* 1999;66:457–61.
16. Borman P, Babaoglu S, Gur G, Bingol S, Bodur H. Bone mineral density and bone turnover in patients with psoriatic arthritis. *Clin Rheumatol.* 2008;27:443–7.
17. Frediani B, Allegri A, Falsetti P, Storri L, Bisogno S, Baldi F, et al. Bone mineral density in patients with psoriatic arthritis. *J Rheumatol.* 2001;28:138–43.
18. Hofbauer LC, Schoppert M, Christ M, Teichmann J, Lange U. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. *Rheumatology (Oxford).* 2006;45:1218–22.
19. Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. *Arthritis Res Ther.* 2011;13:R16.
20. Nolla JM, Gomez-Vaquero C, Romera M, Roig-Vilaseca D, Rozadilla A, Mateo L, et al. Osteoporotic vertebral fracture in clinical practice. 669 Patients diagnosed over a 10 year period. *J Rheumatol.* 2001;28:2289–93.